Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
29807757
DOI
10.1016/j.jstrokecerebrovasdis.2018.05.004
PII: S1052-3057(18)30222-2
Knihovny.cz E-resources
- Keywords
- Acute ischemic stroke, anticoagulation, antidote, dabigatran, intravenous thrombolysis, reversal,
- MeSH
- Antidotes adverse effects therapeutic use MeSH
- Anticoagulants adverse effects therapeutic use MeSH
- Cerebral Hemorrhage etiology MeSH
- Stroke drug therapy mortality MeSH
- Dabigatran adverse effects therapeutic use MeSH
- Fibrinolytic Agents administration & dosage adverse effects MeSH
- Antibodies, Monoclonal, Humanized adverse effects therapeutic use MeSH
- Administration, Intravenous MeSH
- Brain Ischemia drug therapy mortality MeSH
- Humans MeSH
- Recombinant Proteins administration & dosage adverse effects MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Tissue Plasminogen Activator administration & dosage adverse effects MeSH
- Thrombolytic Therapy * adverse effects MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Antidotes MeSH
- Anticoagulants MeSH
- Dabigatran MeSH
- Fibrinolytic Agents MeSH
- Antibodies, Monoclonal, Humanized MeSH
- idarucizumab MeSH Browser
- Recombinant Proteins MeSH
- Tissue Plasminogen Activator MeSH
BACKGROUND: Intravenous thrombolysis (IVT) is contraindicated in patients with acute ischemic stroke (AIS) using oral anticoagulants. A specific human monoclonal antibody was introduced to reverse immediately the anticoagulation effect of the direct inhibitor of thrombin, dabigatran. Until now, mostly individual cases presenting with successful IVT after a reversal of dabigatran anticoagulation in patients with AIS were published. Thus, we aimed to report real-world data from clinical practice. METHODS: Patients with AIS on dabigatran treated with IVT after antidote reversal were enrolled in the retrospective nationwide study. Neurological deficit was scored using the National Institutes of Health Stroke Scale (NIHSS) and 90-day clinical outcome using modified Rankin scale (mRS) with a score 0-2 for a good outcome. Intracerebral hemorrhage (ICH) was defined as a presence of any sign of bleeding on control imaging after IVT, and symptomatic intracerebral hemorrhage (SICH) was assessed according to the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) criteria. RESULTS: In total, 13 patients (7 men, mean age 70.0 ± 9.1 years) with a median NIHSS admission score of 7 points were analyzed. Of these patients, 61.5% used 2 × 150 mg of dabigatran daily. Antidote was administrated 427 ± 235 minutes after the last intake of dabigatran, with a mean activated prothrombin time of 38.1 ± 27.8 seconds and a mean thrombin time of 72.2 ± 56.1 seconds. Of the 13 patients, 2 had ICH and 1 had SICH, and no other bleeding complications were observed after IVT. Of the total number of patients, 76.9% had a good 3-month clinical outcome and 3 patients (23.1%) died. Recurrent ischemic stroke occurred in 2 patients (15.4%). CONCLUSION: The data presented in the study support the safety and efficacy of IVT after the reversal of the anticoagulation effect of dabigatran with antidote in a real-world clinical practice.
References provided by Crossref.org
Effect of Apixaban Pretreatment on Alteplase-Induced Thrombolysis: An In Vitro Study
